• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Eur Acad Dermatol Venereol . Rapidly progressive alopecia areata totalis in a Covid-19 patient, unresponsive to tofacitinib

tetano

Editor, Senior Moderator
J Eur Acad Dermatol Venereol


. 2021 Feb 15.
doi: 10.1111/jdv.17170. Online ahead of print.
Rapidly progressive alopecia areata totalis in a Covid-19 patient, unresponsive to tofacitinib


S Berbert Ferreira[SUP] 1 2 [/SUP], M F R Gavazzoni Dias[SUP] 3 [/SUP], R Berbert Ferreira[SUP] 2 4 [/SUP], A C Neves Neto[SUP] 4 [/SUP], R M Tr?eb[SUP] 5 6 [/SUP], O Lupi[SUP] 7 8 [/SUP]



Affiliations

Abstract

Alopecia areata (AA) is a common autoimmune disease characterized by non-scarring hair loss. (1) Tofacitinib is an effective oral JAK 1/3 inhibitor that can block IL-2, IL-7 and IL-6 and is reported as an option for alopecia areata treatment.(2,3) Though some JAK inhibitors are possible new treatments for severe acute respiratory syndrome coronavirus disease, no treatment of Covid-19 with tofacitinib has been reported to date and the withdrawal of the drug in patients with alopecia areata that become infected with the virus, is controversial.

Keywords: Alopecia Areata; Anti-JAK; COVID-19; Corona Virus; Janus Kinase Inhibitor; SARs COV 2; Tofacitinib.
 
Back
Top Bottom